Tao Li

13PUBLICATIONS
10CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityCellular interactions (incl. adhesion, matrix, cell wall)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Apr 13, 2026
Real-world efficacy and safety of disitamab vedotin (RC48) plus PD-1 inhibitors in advanced urothelial carcinoma: a single-center retrospective study.

Ya-Hui Lv, Xiao-Ran Cui, Lu Yu

|Mar 02, 2026
Efficacy and safety of immunotherapy in elderly patients with advanced non-small cell lung cancer: a real-world study stratified by age.

Yi Dong, Mei-Cen Liu, Yun-Ye Mao

|Feb 12, 2026
Grade 3 and above opportunistic pneumonia or drug-induced interstitial lung disease during tyrosine-kinase inhibitor treatment for advanced non-small-cell lung cancer with RET fusion mutations: coexistence of risks and opportunities.

An Wang, Tao Li, Yun-Ye Mao

|Jan 23, 2026
Clinical Analysis of Peripheral Blood Indicators for Immune-Related Adverse Events (irAEs) in Patients With Advanced Lung Cancer.

Yin-Min Ji, Yu-Hui Qin, Ya-Hui Lv

|Oct 14, 2025
The NLRP3 inflammasome: a pivotal orchestrator of multisystem diseases-from molecular mechanisms to therapeutic innovation.

Shu-Yan Xiao, Ya-Hui Lv, Yin-Min Ji

|Jul 28, 2025
Systematic pan-cancer analysis identified NCOA4 as an immunological and prognostic biomarker and validated in lung adenocarcinoma.

An Wang, Yun-Ye Mao, Tao Li

Pageof 3

Frequent Collaborators

12 joint publications

Yi Hu

5 joint publications

Xiaoran Cui

3 joint publications

An Wang

3 joint publications

Tong Zhang